Access Statistics for Frank Lichtenberg

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A reexamination using data from the U.S. and Australia 0 0 0 15 0 0 0 130
Benefits and Costs of Newer Drugs: An Update 0 0 1 261 0 0 2 647
CONTRIBUTIONS TO FEDERAL ELECTION CAMPAIGNS BY GOVERNMENT CONTRACTORS 0 0 0 1 0 0 0 893
CROWDING OUT: THE IMPACT OF THE STRATEGIC DEFENSE INITIATIVE ON U.S. CIVILIAN R&D INVESTMENT AND INDUSTRIAL COMPETITIVENESS 0 0 0 0 0 0 1 893
Computer Use and Productivity Growth in Federal Government Agencies, 1987 to 1992 0 0 0 190 0 1 1 1,418
Computer Use and Productivity Growth in federal Government Agencies 0 0 0 0 0 0 2 1,411
Does Misery Love Company? Evidence from pharmaceutical markets before and after the Orphan Drug Act 0 0 1 152 0 0 4 775
Does foreign direct investment transfer technology across borders? 0 0 0 0 0 3 4 562
Errors of Measurement in Output Deflators 0 0 0 49 0 0 0 234
GOVERNMENT SUBSIDIES TO PRIVATE MILITARY R&D INVESTMEN: DOD'S IR&D POLICY 0 0 0 1 1 1 2 719
Government Subsidies to Private Military R&D Investment: DOD's IR&D Policy 0 0 2 115 0 0 3 591
HOW ELASTIC IS THE GOVERNMENT'S DEMAND FOR WEAPONS? 0 0 0 0 0 0 0 384
Has medical innovation reduced cancer mortality? 0 0 0 67 1 1 5 235
Have Newer Cardiovascular Drugs Reduced Hospitalization? Evidence From Longitudinal Country-Level Data on 20 OECD Countries, 1995-2003 0 0 0 40 0 0 0 198
How Elastic is the Government's Demand for Weapons? 0 0 0 27 0 1 2 227
How Many Life-Years Have New Drugs Saved? A 3-Way Fixed-Effects Analysis of 66 Diseases in 27 Countries, 2000-2013 0 0 0 53 1 1 4 65
IR&D Project Data and Theories of R&D Investment 0 0 0 76 0 0 5 384
Impact of Specialization on Health Outcomes – Evidence from U.S. Cancer Data 0 0 0 47 0 0 1 180
Importation and Innovation 0 0 0 58 0 1 1 314
Industrial De-Diversification and Its Consequences for Productivity 0 0 0 7 0 0 1 62
Industrial De-Diversification and its Consequences for Productivity 0 0 0 68 0 0 0 298
International R&D Spillovers: A Re-Examination 1 1 2 448 1 2 8 1,194
International R&D spillovers comment 0 0 0 10 0 1 2 213
Labor Market Institutions, Liquidity Constraints, and Macroeconomic Stability 0 0 0 20 0 1 1 141
Listen to your Doctor, or else!: Medication Under-use and Overuse and Long-term Health Outcomes of Danish Diabetes Patients 0 0 0 23 0 0 2 70
Ownership Structure and Corporate Performance in Japan 0 0 0 228 0 0 2 735
Pharmaceutical Innovation and Longevity Growth in 30 Developing and High-income Countries, 2000-2009 0 0 3 99 1 1 8 230
Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010 0 0 0 23 0 0 1 148
Pharmaceutical Innovation, Mortality Reduction, and Economic Growth 0 1 1 376 0 2 6 1,636
Pharmaceutical innovation and the longevity of Australians: a first look 0 0 0 55 0 0 0 212
Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as "equipment for your health" 0 0 0 217 0 0 2 897
Private Investment in R&D to Signal Ability to Perform Government Contracts 0 0 0 19 0 0 0 149
R and D and Productivity at the Industry Level: Is There Still a Relationship? 0 0 2 251 0 0 4 634
R&D Investment and International Productivity Differences 0 0 6 448 2 4 19 1,254
Response to Baker and Fugh-Berman's Critique of my Paper, "Why has Longevity Increased more in some States than in others?" 0 0 0 14 0 1 5 122
Sources of U.S. Longevity Increase, 1960 -1997 0 0 0 59 1 1 3 613
Sources of U.S. Longevity Increase, 1960-1997 0 0 1 183 0 1 2 981
Spurious correlation in estimation of the health production function: A note 0 0 0 90 1 1 4 431
THE EFFECT OF TAKEOVERS ON THE EMPLOYMENT AND WAGES OF CENTRAL-OFFICE AND OTHER PERSONNEL 0 0 0 1 0 0 1 440
Technical Change, Learning, and Wages 0 0 0 37 0 2 6 178
The Allocation of Publicly-Funded Biomedical Research 0 0 0 68 0 0 1 1,025
The Allocation of Publicly-Funded Biomedical Research 0 0 0 47 0 0 0 496
The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey 0 0 0 181 0 0 2 711
The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey 0 0 0 61 0 0 1 401
The Comparative Advantage of Educated Workers in Implementing New Technology: Some Empirical Evidence 0 0 1 116 0 0 4 481
The Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France 0 0 0 59 0 0 1 230
The Dual Effects of Intellectual Property Regulations: Within- and Between- Patent Competition in the US Pharmaceuticals Industry 0 0 0 283 0 0 1 947
The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in The US Pharmaceuticals Industry 0 0 0 0 0 0 3 5
The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the US 0 0 0 37 0 0 0 135
The Effect Of Takeovers On The Employment And Wages Of Central-Office And Other Personnel 0 0 0 358 0 1 4 1,329
The Effect of Changes in Drug Utilization on Labor Supply and Per Capita Output 0 0 2 65 0 1 6 355
The Effect of Drug Vintage on Survival: Micro Evidence from Puerto Rico's Medicaid Program 0 0 0 45 0 1 1 387
The Effect of Education on Medical Technology Adoption: Are the More Educated More Likely to Use New Drugs 0 0 1 137 0 1 5 895
The Effect of New Drugs on Mortality from Rare Diseases and HIV 0 0 0 82 0 0 0 599
The Effect of New Political Administration on Federal Government Productivity and Employment 0 0 0 1 0 0 1 444
The Effect of New Political Administration on Federal Government Productivity and Employment 0 0 0 116 0 0 1 1,061
The Effect of Pharmaceutical Innovation on Longevity: Patient-Level Evidence from the 1996-2002 Medical Expenditure Panel Survey and Linked Mortality Public-Use Files 0 0 0 48 0 0 0 102
The Effect of Pharmaceutical Innovation on the Functional Limitations of Elderly Americans Evidence from the 2004 National Nursing Home Survey 0 0 0 26 0 0 0 74
The Effect of Pharmaceutical Utilization and Innovation on Hospitalization and Mortality 0 0 1 157 0 0 7 575
The Effect of Takeovers on the Employment and Wages of Central-Office and Other Personnel 0 0 0 197 0 0 2 491
The Effects Of Leveraged Buyouts On Productivity And Related Aspects Of Firm Behavior 0 0 0 1,036 0 2 8 2,503
The Effects of Leveraged Buyouts on Productivity and Related Aspects of Firm Behavior 0 0 2 519 0 0 6 1,320
The Effects of Mergers on Prices, Costs, And Capacity Utilization in the U.S. Air Transportation Industry, 1970-84 0 0 0 11 0 0 1 44
The Effects of Mergers on Prices, Costs, and Capacity Utilization in the U.S. Air Transportation Industry, 1970-84 0 0 0 62 1 1 1 344
The Effects of Off-label Drug Use on Disability and Medical Expenditure 0 0 0 9 0 0 4 15
The European Strategic Program for Research in Information Technologie (ESPRIT): An Ex-Post Analysis 0 0 0 0 1 4 10 1,126
The Expanding Pharmaceutical Arsenal in the War on Cancer 0 0 0 113 0 0 0 405
The Impact and Organization of Publicly-Funded Research and Development in the European Community 0 0 0 117 0 0 1 892
The Impact of Biomedical Knowledge Accumulation on Mortality: A Bibliometric Analysis of Cancer Data 0 0 0 2 0 0 1 48
The Impact of Hospital Quality-Related Practices on Health Outcomes 0 0 0 48 0 0 1 243
The Impact of Increased Utilization of HIV Drugs on Longevity and Medical Expenditures: An Assessment Based on Aggregate U.S. Time-Series Data 0 1 1 49 0 1 2 366
The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries 0 0 0 13 0 0 0 43
The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries 0 0 0 3 0 0 0 33
The Impact of New Laboratory Procedures and Other Medical Innovations on the Health of Americans, 1990-2003: Evidence from Longitudinal, Disease-Level Data 0 0 0 35 0 0 0 270
The Impact of Pharmaceutical Innovation on Longevity and Medical Expenditure in Sweden, 1997-2010: Evidence from Longitudinal, Disease-Level Data 0 0 0 25 1 1 3 116
The Impact of Pharmaceutical Innovation on Premature Cancer Mortality in Canada, 2000-2011 0 0 0 37 0 0 1 61
The Impact of Public and Private Research Support on Premature Cancer Mortality and Hospitalization in the U.S., 1999-2013 0 0 0 34 1 1 5 44
The Impact of R&D Investment On Productivity - New Evidence Using Linked R&D-LRD Data 0 1 2 493 0 2 10 990
The Impact of Recent Chemotherapy Innovation on the Longevity of Myeloma Patients: U.S. and International Evidence 0 0 0 9 0 0 3 88
The Impact of Therapeutic Procedure Innovation on Hospital Patient Longevity: Evidence from Western Australia, 2000-2007 0 0 1 17 0 1 3 90
The Long-run Impact of New Medical Ideas on Cancer Survival and Mortality 0 0 0 33 0 0 0 41
The Output Contributions of Computer Equipment and Personnel: A Firm- Level Analysis 0 0 1 195 0 1 7 784
The Quality of Medical Care, Behavioral Risk Factors, and Longevity Growth 0 0 0 187 0 0 0 689
The effects of off-label drug use on disability and medical expenditure 0 0 1 2 0 0 5 10
The expanding pharmaceutical arsenal in the war on cancer 0 0 0 119 0 0 0 536
The impact of new drug launches on hospitalization in 2015 for 67 medical conditions in 15 OECD countries: a two-way fixed-effects analysis 0 0 1 27 0 0 2 77
The impact of new drug launches on longevity: evidence from longitudinal disease-level data from 52 countries, 1982-2001 0 0 0 203 0 0 1 608
Training, Tenure, and Productivity 0 0 0 61 2 2 3 242
USING LINKED CENSUS R&D-LRD DATA TO ANALYZE THE EFFECT OF R&D INVESTMENT ON TOTAL FACTOR PRODUCTIVITY GROWTH 0 0 1 379 0 1 2 880
Using Patents Data to Map Technical Change in Health-Related Areas 0 0 0 97 0 0 4 269
Total Working Papers 1 4 34 9,847 15 47 238 44,818


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A Reexamination Using Data from the U.S. and Australia 0 0 0 18 0 2 4 184
Are drug prices subject to creative destruction? Evidence from the US, 1997–2017 0 0 1 9 0 0 2 20
Are patients more adherent to newer drugs? 0 0 0 1 0 0 3 25
Are the More Educated More Likely to Use New Drugs? 0 0 5 20 0 1 14 74
Benefits and costs of newer drugs: an update 0 0 1 88 0 1 5 427
Book Reviews 0 0 0 3 0 0 0 18
Changing market opportunities and the structure of R & D investment: The case of energy 0 0 0 10 0 0 1 64
Computer Use and Productivity Growth in US Federal Government Agencies, 1987–92 0 0 0 1 0 0 2 10
Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France, 2001–7 0 0 0 11 1 2 6 126
Contributions to Federal Election Campaigns by Government Contractors 0 0 1 19 0 0 3 306
Do (More and Better) Drugs Keep People Out of Hospitals? 0 0 0 281 0 0 1 665
Does Foreign Direct Investment Transfer Technology Across Borders? 1 3 12 671 1 8 40 1,830
Does competition stimulate drug utilization? The impact of changes in market structure on US drug prices, marketing and utilization 1 1 4 70 1 2 6 226
Energy prices and induced innovation 0 0 0 58 0 0 0 114
Errors of Measurement in Output Deflators 0 0 0 0 0 0 0 249
Estimation of the Internal Adjustment Costs Model Using Longitudinal Establishment Data 0 0 1 23 0 0 2 148
Has Medical Innovation Reduced Cancer Mortality? 0 0 1 7 0 0 2 52
Has Pharmaceutical Innovation Reduced Social Security Disability Growth? 0 0 0 12 0 0 0 63
Has Using Newer Drugs Reduced Admissions to Hospitals and Nursing Homes? 0 0 0 22 0 0 2 101
Has pharmaceutical innovation reduced the average cost of U.S. health care episodes? 0 0 1 2 0 1 7 9
Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country‐level data on 20 OECD countries, 1995–2003 0 0 0 26 0 0 3 273
How elastic is the government's demand for weapons? 0 1 2 18 0 3 9 202
IMPORTATION AND INNOVATION 0 0 0 28 0 0 4 340
IR & D project data and theories of R & D investment 0 0 0 6 0 0 1 54
Industrial de-diversification and its consequences for productivity 0 0 0 48 0 1 5 227
Information technology and its impact on firm-level productivity: evidence from government and private data sources, 1977-1993 1 1 1 220 1 2 7 749
Interindustry Technology Flows and Productivity Growth: A Re-examination 0 0 7 247 1 2 18 618
International R&D spillovers: A comment 0 1 2 369 0 1 8 993
Issues in measuring industrial R&D 0 0 0 26 0 0 1 76
Labour market institutions, liquidity constraints, and macroeconomic stability 0 0 0 9 0 0 1 129
Managerial ownership and firm performance: A re-examination using productivity measurement 0 0 4 189 0 0 11 466
Ownership structure and corporate performance in Japan 0 0 2 123 0 2 14 461
Pharmaceutical Innovation and U.S. Cancer Survival, 1992-2003: Evidence from Linked SEER-MEDSTAT Data 0 0 0 39 0 0 2 209
Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010 0 0 0 11 0 0 1 93
Pharmaceutical Price Discrimination and Social Welfare 0 0 0 62 0 1 3 277
Pharmaceutical innovation and mortality in the United States, 1960-2000. A commentary on Schnittker and Karandinos 0 0 1 25 0 0 1 81
Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as 'Equipment for Your Health' 0 0 0 39 0 0 2 303
Productivity and Changes in Ownership of Manufactoring Plants 0 0 1 108 0 0 6 398
Rejoinder to comment by Maarten Vendrik 0 0 0 11 0 0 1 122
Sources of U.S. longevity increase, 1960-2001 0 0 2 154 0 1 6 502
Spurious correlation in estimation of the health production function: A note 0 0 0 58 0 0 4 388
THE EFFECT OF CONTROL CHANGES ON THE PRODUCTIVITY OF U.S. MANUFACTURING PLANTS 0 0 2 26 0 0 5 66
THE IMPACT OF NEW DRUG LAUNCHES ON LIFE-YEARS LOST IN 2015 FROM 19 TYPES OF CANCER IN 36 COUNTRIES 0 0 0 0 0 0 3 5
Testing the Convergence Hypothesis 0 0 2 353 1 2 5 1,327
The Comparative Advantage of Educated Workers in Implementing New Technology 0 0 3 809 2 5 19 3,818
The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the U.S. Pharmaceuticals Industry 0 0 1 31 0 0 5 284
The Effect of Government Funding on Private Industrial Research and Development: A Re-assessment 2 2 7 232 2 3 10 663
The Effect of Ownership Changes on the Employment and Wages of Central Office and Other Personnel 0 0 1 16 0 0 3 442
The Effect of Pharmaceutical Innovation on Longevity: Patient Level Evidence from the 1996–2002 Medical Expenditure Panel Survey and Linked Mortality Public-use Files 0 1 1 41 1 2 4 221
The Effect of Using Newer Drugs on Admissions of Elderly Americans to Hospitals and Nursing Homes: State-level Evidence from 1997 to 2003 0 0 0 2 0 1 2 59
The Effects of Medicare on Health Care Utilization and Outcomes 0 0 0 139 0 0 0 945
The Health Impact of, and access to, New Drugs in Korea 0 0 0 3 2 2 5 19
The Impact and Organization of Publicly-Funded Research and development in the European Community 0 0 0 2 0 0 0 139
The Impact of Biopharmaceutical Innovation on Disability, Social Security Recipiency, and Use of Medical Care of U.S. Community Residents, 1998–2015 0 0 1 2 0 0 1 5
The Impact of New Drug Launch on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries 0 0 0 6 0 1 7 58
The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: A Two-Way Fixed-Effects Analysis 0 0 1 8 0 0 7 35
The Impact of New Drug Launches on Longevity Growth in Nine Middle Eastern and African Countries, 2007–2015 0 0 0 15 0 3 3 70
The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982–2001 0 0 0 120 0 1 2 471
The Impact of New Drugs on US Longevity and Medical Expenditure, 1990–2003: Evidence from Longitudinal, Disease-Level Data 0 0 0 59 0 1 4 250
The Impact of Pharmaceutical Innovation on Cancer Mortality in Belgium, 2004–2012 0 0 0 6 1 1 1 53
The Impact of Pharmaceutical Innovation on Disability Days and the Use of Medical Services in the United States, 1997-2010 0 0 0 27 0 1 2 90
The Impact of Pharmaceutical Innovation on Premature Mortality, Cancer Mortality, and Hospitalization in Slovenia, 1997–2010 0 0 0 5 0 0 2 60
The Impact of Pharmaceutical Innovation on Premature Mortality, Hospital Separations, and Cancer Survival in Australia 0 0 1 6 1 1 3 40
The Impact of Public and Private Research on Premature Cancer Mortality and Hospitalization in the United States, 1999-2013 0 0 0 2 0 0 0 14
The Impact of R&D Investment on Productivity--New Evidence Using Linked R&D-LRD Data 0 0 0 0 0 3 10 1,053
The Managerial Response to Regulation of Financial Reporting for Segments of a Business Enterprise 0 0 0 1 0 0 2 340
The Private R&D Investment Response to Federal Design and Technical Competitions 0 2 3 198 2 8 12 722
The Relationship between Federal Contract R&D and Company R&D 0 0 0 9 0 5 11 710
The association between pharmaceutical innovation and both premature mortality and hospital utilization in Switzerland, 1996–2019 0 2 4 4 0 2 5 11
The benefits to society of new drugs: a survey of the econometric evidence 0 0 0 77 0 0 1 402
The burden of government:, Stanford: Hoover Institution Press, 1986. x + 188 pp., $23.95 0 0 0 3 0 0 0 51
The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978-2004 0 0 0 84 0 0 6 458
The effect of new drug approvals on HIV mortality in the US, 1987-1998 0 0 0 16 0 0 0 108
The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999–2010 0 0 0 5 0 0 1 56
The effect of pharmaceutical innovation on longevity: Evidence from the U.S. and 26 high-income countries 0 0 0 0 0 0 1 2
The effects of dynamic and static competition on prescription drug prices in Denmark, 1997–2017 0 0 0 2 1 1 3 9
The effects of leveraged buyouts on productivity and related aspects of firm behavior 2 3 12 591 5 16 64 1,685
The impact of biomedical innovation on the disability of elderly Medicare recipients, 2013–2019 0 0 1 1 0 0 4 6
The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999–2007 0 0 0 2 0 0 0 39
The impact of pharmaceutical innovation on cancer mortality in Mexico, 2003–2013 0 1 1 2 0 2 5 37
The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000–2009 0 0 0 34 1 1 4 132
The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997-2010: evidence from longitudinal, disease-level data 0 0 0 5 0 1 4 75
The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000–2011 0 0 0 8 0 1 5 78
The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence 0 0 0 5 1 1 2 50
The impact of therapeutic procedure innovation on hospital patient longevity: Evidence from Western Australia, 2000–2007 0 0 0 5 0 0 2 131
The long-run impact of new medical ideas on cancer survival and mortality 0 0 0 3 0 0 0 22
The quality of medical care, behavioral risk factors, and longevity growth 0 0 0 32 0 0 2 246
Total Journal Articles 7 18 90 6,139 25 95 445 27,229


Chapter File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Are the More Educated More Likely to Use New Drugs? 0 0 0 0 0 0 3 115
Economics of defense R&D 0 3 4 465 0 5 9 1,251
Pharmaceutical Innovation and US Cancer Survival, 1992-2003: Evidence from Linked SEER-MEDSTAT Data 0 0 0 0 0 0 0 11
Pharmaceutical Knowledge-Capital Accumulation and Longevity 0 0 1 33 0 0 2 120
Pharmaceutical innovation and the longevity of Australians: A first look 0 0 0 0 0 0 0 2
R&D and Productivity Growth at the Industry Level: Is There Still a Relationship? 0 1 3 175 0 2 9 448
The Allocation of Publicly Funded Biomedical Research 0 0 0 13 2 3 15 81
The Effect of Pharmaceutical Innovation on the Functional Limitations of Elderly Americans: Evidence from the 2004 National Nursing Home Survey 0 0 0 0 0 0 1 1
The Effects of Medicare on Health Care Utilization and Outcomes 0 0 1 347 0 0 6 4,189
The Impact of Biomedical Research on U.S. Cancer Mortality: A Bibliometric Analysis 0 0 0 10 0 0 1 49
The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger 0 0 1 15 2 2 6 46
The effect of drug vintage on survival: Micro evidence from Puerto Rico's Medicaid program 0 0 0 0 0 0 2 2
The impact of biomedical innovation on longevity and health 0 0 0 1 1 3 7 13
Total Chapters 0 4 10 1,059 5 15 61 6,328
3 registered items for which data could not be found


Statistics updated 2025-07-04